Trial
NCT03131206
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Genentech, Inc.
Condition
ALK-positive Non-small Cell Lung Cancer (NSCLC)
Intervention
Alectinib
Why stopped
Study closed due to slow accrual and lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-27